LeadIQ logo
Learn more at LeadIQ.com

Insights

Innovative Therapy Pipeline Cantargia specializes in antibody-based therapies targeting IL1RAP, with ongoing clinical development of Nadunolimab (Phase II) for cancer and CAN10 (Phase I) for autoimmune and inflammatory diseases, indicating active growth opportunities in the biotech and pharma sectors.

Strategic Industry Engagement The company actively participates in high-profile industry conferences such as AACR and Van Lanschot Kempen's Life Sciences Conference, providing avenues for networking, partnership development, and visibility to potential collaborators and investors.

Recent Leadership Expansion Recent appointments of a new CEO and a Chief Medical Officer highlight organizational growth and a focus on strengthening scientific and strategic expertise, which can attract partners looking for committed and experienced biotech collaborators.

Partnership & Asset Acquisition Otsuka Pharmaceutical's recent acquisition of assets related to CAN10 demonstrates the company's potential to attract major pharmaceutical partners interested in innovative autoimmune and cancer therapies.

Funding & Market Presence Despite a modest funding level of $2.6 million, Cantargia's active engagement in conferences and strategic partnerships positions it as a promising candidate for additional investment and collaboration opportunities.

Similar companies to Cantargia AB

Cantargia AB Tech Stack

Cantargia AB uses 8 technology products and services including iCIMS, Google Hosted Libraries, Craft CMS, and more. Explore Cantargia AB's tech stack below.

  • iCIMS
    Applicant Tracking Systems
  • Google Hosted Libraries
    Content Delivery Network
  • Craft CMS
    Content Management System
  • Microsoft 365
    Email
  • Google Fonts API
    Font Scripts
  • PHP
    Programming Languages
  • Google Analytics
    Web Analytics
  • Apache HTTP Server
    Web Servers

Cantargia AB's Email Address Formats

Cantargia AB uses at least 1 format(s):
Cantargia AB Email FormatsExamplePercentage
First.Last@cantargia.comJohn.Doe@cantargia.com
89%
First.MiddleLast@cantargia.comJohn.MichaelDoe@cantargia.com
8%
LastFirst@cantargia.comDoeJohn@cantargia.com
1%
First.Middle@cantargia.comJohn.Michael@cantargia.com
2%

Frequently Asked Questions

Where is Cantargia AB's headquarters located?

Minus sign iconPlus sign iconCantargia AB's main headquarters is located at 27 Scheelevägen Lund, Skåne 223 63 Sweden. The company has employees across 1 continents, including Europe.

What is Cantargia AB's phone number?

Minus sign iconPlus sign icon You can contact Cantargia AB's main corporate office by phone at
+46-46-275-6****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cantargia AB's official website and social media links?

Minus sign iconPlus sign iconCantargia AB's official website is cantargia.com and has social profiles on LinkedInCrunchbase.

What is Cantargia AB's SIC code NAICS code?

Minus sign iconPlus sign iconCantargia AB's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cantargia AB have currently?

Minus sign iconPlus sign iconAs of May 2026, Cantargia AB has approximately 31 employees across 1 continents, including Europe. Key team members include Ceo: H. H. S.Chief Business Officer: T. B.Chief Financial Officer: P. R.. Explore Cantargia AB's employee directory with LeadIQ.

What industry does Cantargia AB belong to?

Minus sign iconPlus sign iconCantargia AB operates in the Biotechnology Research industry.

What technology does Cantargia AB use?

Minus sign iconPlus sign iconCantargia AB's tech stack includes iCIMSGoogle Hosted LibrariesCraft CMSMicrosoft 365Google Fonts APIPHPGoogle AnalyticsApache HTTP Server.

What is Cantargia AB's email format?

Minus sign iconPlus sign iconCantargia AB's email format typically follows the pattern of First.Last@cantargia.com. Find more Cantargia AB email formats with LeadIQ.

How much funding has Cantargia AB raised to date?

Minus sign iconPlus sign icon As of May 2026, Cantargia AB has raised $2.6M in funding. The last funding round occurred on Jun 17, 2025 for $2.6M.

When was Cantargia AB founded?

Minus sign iconPlus sign iconCantargia AB was founded in 2010.

Cantargia AB

Biotechnology ResearchSkåne, Sweden11-50 Employees

Cantargia AB is a biotechnology research company based in Lund, Sweden, focused on developing antibody-based therapies that target IL1RAP. Its clinical portfolio includes nadunolimab in phase II for cancer and CAN10 in phase I for autoimmune and inflammatory diseases. The company employs 11-50 people and is located at 27 Scheelevägen, Lund, Skåne, 223 63, Sweden, with a website at cantargia.com. In 2025 the company underwent leadership changes, appointing Hilde Steineger as Chief Executive Officer in August, and appointing Wolfram Dempke as Chief Medical Officer in October, following the departure of Morten Lind Jensen from the CMO role in March 2025; Otsuka also announced an asset purchase related to CAN10 in 2025. Public disclosures indicate revenue in the 0 to 1 million USD range and funding of about 2.6 million USD.

Section iconCompany Overview

Headquarters
27 Scheelevägen Lund, Skåne 223 63 Sweden
Phone number
+46-46-275-6****
Website
cantargia.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2010
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $2.6M

    Cantargia AB has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jun 17, 2025 in the amount of $2.6M.

  • $1M

    Cantargia AB's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $2.6M

    Cantargia AB has raised a total of $2.6M of funding over 3 rounds. Their latest funding round was raised on Jun 17, 2025 in the amount of $2.6M.

  • $1M

    Cantargia AB's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    H. H. S.
    Ceo
    Phone icon
    Mobile Phone
  • Stylized image of a person
    T. B.
    Chief Business Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    P. R.
    Chief Financial Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. L.
    Chief Scientific Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. T.
    Vp Clinical Development
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    L. T.
    Vp Clinical Development
    Phone icon
    Mobile Phone
  • Stylized image of a person
    N. L.
    Vp Biometrics
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. M.
    Non Executive Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. S.
    Project Director
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. D. G. T.
    Senior Project Director
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.